Group Medical Director’s Report

Professor Luk Rombauts
Group Medical Director, Monash IVF Group

As the inaugural Group Medical Director for the Monash IVF Group of companies I am pleased to announce the progress we have made in improving and enhancing our medical processes and the sharing of expertise and innovation across the group.

We have established two peak committees that will help us to maintain our scientific leadership and competitive edge in IVF and womens imaging. They will also assist with the cross pollination of best practice clinical protocols and innovation across the group.

The role of the Group Medical Advisory Committee (GMAC) is to ensure patients receive the best possible personalised care through establishing and maintaining optimal clinical processes and procedures.

The second key committee is the Group Medical Executive Committee (GMEC) which facilitates appropriate consultation and communication in relation to relevant commercial and operational matters with medical practitioners across the Group.

We’ve already made great inroads into a number of areas. A framework for succession planning is well advanced to develop career pathways for younger doctors and scientists. This will ensure suitable transitional arrangements and career/professional advancement opportunities are available across the Group. We expect this will further strengthen Monash IVF Group’s position as the employer of choice in fertility services.

The Group’s live birth rates – the critical outcome by which our industry gets measured – remain amongst the best internationally and continue to improve across all age cohorts. We are very proud of our ability to translate new scientific developments and innovations efficiently and effectively into our daily work practices to give our patients access to cutting-edge fertility care. We are fortunate that much of the research that drives our clinical innovation is generated by leading investigators within the Monash IVF Group.

As a group of companies with more than 500 laboratory and medical staff we have been able to develop strong mechanisms to disseminate clinical best practice across the group. This has a few elements including disseminating the latest research – both internally and from around the world. We also review the most difficult cases internally to see whether there are common themes or whether other group members can contribute their expertise.

Our capability to provide crucial services in womens imaging has also greatly strengthened with a rapidly growing team of clinicians and technicians highly skilled in ultrasound scanning of the infertile and pregnant woman. Their services have recently expanded to include screening for early onset preeclampsia, a severe complication of pregnancy. In addition, non-invasive prenatal testing (NIPT) will now be offered through a fast and high-quality in-house service allowing expecting mothers to have their first trimester pregnancies to be genetically screened in a safe and affordable way.

We are proud of all these outcomes that come as a result of the synergies that exist between our research teams, scientists and clinical staff and we look forward to further contributing to the industry with “excellence in science and care”.